araag2/HINT huggingface dataset:
Clinical trial NCT00104988 (phase 2, status: completed)
Conditions: melanoma (skin)
ICD codes: C43.51, C43.9, C43.52, D03.51, C43.8, Z85.820, D03.52
Drugs: temozolomide, thalidomide
SMILES: CSCC[C@H](N)C(O)=O, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant cutaneous melanoma

               -  Unresectable, stage IV disease

               -  Unknown primary allowed

          -  Measurable or non-measurable disease

               -  If all known sites of disease are within a previously irradiated port, disease
                  progression must be clearly demonstrated

          -  No brain metastases by CT scan or MRI within the past 42 days

               -  Prior brain metastasis allowed provided both of the following criteria are met:

                    -  Completely resected and free of disease

                    -  Treated with whole brain radiotherapy and completed treatment at least 28
                       days ago

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL (transfusions allowed)

        Hepatic

          -  Bilirubin ≤ 3 times upper limit of normal (ULN)

          -  SGOT or SGPT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)

        Renal

          -  Creatinine ≤ 1.5 times ULN

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-method contraception for 4 weeks before,
             during, and for 4 weeks after study participation

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer in complete remission

          -  No history of allergic reaction to dacarbazine

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior thalidomide for stage IV disease

          -  At least 28 days since prior biological therapy

          -  At least 28 days since prior immunotherapy

          -  At least 28 days since prior adjuvant interferon alfa

        Chemotherapy

          -  No prior temozolomide or dacarbazine for stage IV disease

          -  At least 28 days since prior chemotherapy

        Endocrine therapy

          -  At least 28 days since prior hormonal therapy

        Radiotherapy

          -  See Disease Characteristics

          -  At least 28 days since prior radiotherapy

        Surgery

          -  See Disease Characteristics

          -  At least 28 days since prior surgery for primary and stage IV disease

        Other

          -  No more than 1 prior systemic therapy regimen for stage IV disease

          -  At least 28 days since other prior systemic therapy
Clinical trial NCT00520468 (phase 2, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: erythropoietin, cyclosporin a, g-csf, prednisone
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with MDS and </= 10% blasts or International Prognostic Scoring System (IPSS)
             low or intermediate 1. No prior intensive chemotherapy or high-dose ara-C (>/= 1g/m2).
             Prior cytokines, biologic therapies, targeted therapies, or single agent chemotherapy
             allowed. Procrit, G-CSF are allowed before therapy. Patients with blasts < 5% must
             have an indication for therapy, such as transfusion needs, symptomatic anemia or Hb <
             11g/dl, platelets < 100 x 10 9/L, or granulocytes < 10 9/L.

          2. Performance 0-2 (Eastern Cooperative Oncology Group (ECOG)). Adequate liver function
             (bilirubin of < 2mg/dl) and renal function (creatinine < 2mg/dl). Adequate cardiac
             functions (New York Heart Association (NYHA) cardiac III-IV excluded)

          3. Signed informed consent

        Exclusion Criteria:

          1. Nursing and pregnant females are excluded. Women of childbearing potential should
             practice effective methods of contraception. Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately.

          2. Patients with active and uncontrolled infections.
Clinical trial NCT00349193 (phase 2, status: completed)
Conditions: relapsing remitting multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: laquinimod 0.3, laquinimod 0.6
SMILES: CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Willing and able to give written informed consent

          2. Confirmed MS diagnosis as defined by the McDonald criteria

          3. R-R MS disease course.

          4. At least one gadolinium-enhanced lesion on screening MRI

          5. Women of child-bearing potential must practice a reliable method of birth control.

          6. Must understand the requirements of the study and agree to comply with the study
             protocol.

        Exclusion Criteria:

          1. Subjects who suffer from any form of progressive MS.

          2. Any condition which the investigator feels may interfere with participation in the
             study.

          3. Subjects with a clinically significant or unstable medical or surgical condition that
             would preclude safe and complete study participation,

          4. Subjects who received any investigational medication, immunosuppressives or cytotoxic
             agents within 6 months prior to screening

          5. Previous treatment with immunomodulators within two months prior to screening
Clinical trial NCT00419146 (phase 2/phase 3, status: completed)
Conditions: schizophrenia, schizophreniform disorders, schizoaffective disorder, psychotic disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: ethyl-eicosapentaenoic acid (epa), vitamins e + c
SMILES: CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with schizophrenia, schizophreniform disorder or schizoaffective disorder
             (DSM-IV)

          -  Admitted to a psychiatric hospital/department within the previous twenty-one days
             before screening

          -  Less than fifteen years, in retrospect, since first psychotic symptoms (DSM-IV 295,
             criteria A,1-4)

          -  Age 18-40 years

          -  Speaks fluently a Scandinavian language

          -  A written informed consent must be obtained before any trial-related activities

        Exclusion Criteria:

          -  A diagnosis of substance dependence (DSM-IV)

          -  Known allergy to study medication

          -  Currently taking warfarin or having anamnestic indicators of impaired haemostasis
             (profuse bleeding, except epistaxis)
Clinical trial NCT00600938 (phase 2, status: completed)
Conditions: transfusional iron overload, transfusional hemosiderosis
ICD codes: E87.70, E87.79, E87.71
Drugs: core study: deferasirox, core study: deferoxamine, extension: deferoxamine to deferasirox, extension: deferasirox to deferoxamine, deferasirox, deferoxamine
SMILES: CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Eligibility criteria:

        Inclusion criteria:

          -  Male or female patients, aged 10 years and above, with β-thalassemia major or DBA or
             sideroblastic anemia on chronic transfusion therapy, having given written consent to
             participate in the study.

          -  Patients with cardiac iron as measured by a myocardial T2* value that is ≥ 6ms but not
             ≥ 20 ms.

          -  Patients with a lifetime history of at least 50 units of red cell transfusions, and
             must be receiving at least ≥10 units/yr of red blood cells transfusions.

          -  Patients with a left ventricular ejection fraction (LVEF) ≥ 56 % as determined by
             cardiovascular magnetic resonance (CMR).

          -  Patients with liver iron content (LIC) value ≥ 3 mg Fe / g dw, as determined by liver
             MRI.

        Exclusion criteria:

          -  Patients with clinical symptoms of cardiac dysfunction.

          -  Patients unable to undergo study assessments including MRI

          -  Patients participating in another clinical trial or receiving an investigational drug.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00220805 (phase 2, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: immune globulin intravenous [human], 10% caprylate/chromatography purified, albumin (human) 25%, united states pharmacopeia (usp)
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  The best corrected visual acuity must be in the range of 20/40 to 20/200 on the Early
             Treatment Diabetic Retinopathy Study (ETDRS) chart (0.5 - 0.1).

          -  Patient complaint of visual loss within the last three months prior to study entry.

          -  Documented visual loss on a visual acuity chart in the 3-month period prior to the
             beginning of the run-in period.

          -  Signed written informed consent prior to initiation of any study-related procedures.

        Exclusion Criteria:

          -  Treatment with IGIV within the last 3 months prior to the run-in.

          -  Previous photodynamic therapy (PDT) or vitrectomy or transpupillary thermotherapy
             (TTT) or any specific pre-treatment of CNV

          -  Subfoveal blood in the study eye if ≥ 1/2 disc diameter as measured by slit lamp
             during run-in period.

          -  History of anaphylaxis or severe systemic response to immunoglobulin or with a blood
             product.

          -  Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia
             requiring treatment, unstable or advanced ischemic heart disease, or severe or
             uncontrolled hypertension (diastolic > 95 mmHg or systolic >170 mmHg)

          -  Females, who are pregnant, breast feeding, or if of childbearing potential, unwilling
             to practice adequate contraception throughout the study.

          -  History of renal insufficiency or serum creatinine levels > 221 µmol/L (2.5 mg/dL).

          -  Known selective immunoglobulin A (IgA) deficiency

          -  Other investigational drugs received within the past 3 months.

          -  Conditions whose symptoms and effects could alter protein catabolism and/or
             immunoglobulin (IgG) utilization (e.g. protein-losing enteropathies, nephrotic
             syndrome).

          -  Known hypercoagulable state.

          -  Patients on continuous systemic steroid treatment

          -  Mentally challenged adult subjects who cannot give independent informed consent.

          -  History of thromboembolic events.

          -  Diabetes mellitus requiring drug treatment.

          -  Known severe hypersensitivity to sodium fluorescein.

          -  Acute or known ocular diseases such as glaucoma, arterial or venous occlusions, acute
             ischemic optic-neuropathy, impairment of visual acuity due to opacities in the lens
             (LOCSIII: NO 5-6 or C: 4-5 or P 4-5) or vitreous which may influence the evaluation of
             the therapeutic effect.
Clinical trial NCT00367952 (phase 2, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: apricitabine
SMILES: NC1=NC(=O)N(C=C1)[C@H]1CO[C@@H](CO)S1
Eligibility criteria:

        Inclusion Criteria:

          -  Completed AVX-201 protocol, Plasma HIV RNA <5000 copies/ml, CD4 cells >50

        Exclusion Criteria:

          -  Pregnant or breastfeeding females, withdrawal from AVX-201
Clinical trial NCT00149292 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ly2140023, olanzapine, placebo
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID

        Exclusion Criteria:

          -  meet the full syndromal criteria for other Axis I disorder

          -  have taken any depot antipsychotic within 4 weeks before screening

          -  are taking mood-stabilizing agents
Clinical trial NCT00304512 (phase 2, status: completed)
Conditions: fabry disease
ICD codes: E75.21
Drugs: migalastat hcl
SMILES: OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Females between 18 and 65 years of age (inclusive)

          -  Heterozygous for Fabry disease

          -  Had a confirmed diagnosis of Fabry disease with a documented missense gene mutation
             (individual or familial)

          -  Had enhanceable enzyme activity based on in vitro tests

          -  Were naïve to enzyme replacement therapy (ERT) and other therapies, except for
             palliative therapies for the signs and symptoms of Fabry disease, or stopped ERT for
             at least 18 weeks

          -  Had end organ dysfunction, even minimal, demonstrated by abnormal electrocardiogram
             (ECG) or evidence of left ventricular hypertrophy documented by echocardiogram or by
             cardiac biopsy; or renal insufficiency documented by common clinical assessments such
             as creatinine and glomerular filtration rate or by renal biopsy; or brain tissue
             dysfunction as documented by evidence of stroke (clinically or imaging); or peripheral
             nervous tissue dysfunction documented by complaints of intolerance to heat or cold,
             decreased vibratory sense and proprioception, decreased ability to perspire, or
             acroparesthesia.

          -  Were willing to undergo 2 renal and 3 skin biopsies

          -  Agreed to be sexually abstinent or practice an effective method of contraception when
             engaging in sexual activity during the course of the study and for a period of 30 days
             following their completion of the study for women of childbearing potential.

          -  Were willing and able to provide written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating

          -  History of organ transplant

          -  History of significant disease other than Fabry disease (for example, end-stage renal
             disease; Class III or IV heart disease [per the New York Heart Association
             classification]; current diagnosis of cancer, except for basal cell carcinoma of the
             skin; diabetes [unless hemoglobin A1c ≤8]; or neurological disease that would have
             impaired the participant's ability to participate in the study)

          -  Serum creatinine >176 micromoles/liter on Day -2

          -  Screening 12-lead ECG demonstrating corrected QT interval >450 milliseconds

          -  Pacemaker or other contraindication for magnetic resonance imaging scanning

          -  Taking a medication prohibited by the protocol: Fabrazyme® (agalsidase beta),
             Replagal™ (agalsidase alfa), Glyset® (miglitol), Zavesca® (miglustat), or any
             experimental therapy for any indication

          -  Participated in a previous clinical trial in the last 30 days

          -  Any other condition which, in the opinion of the investigator would jeopardize the
             safety of the participant or impact the validity of the study results.
Clinical trial NCT01736397 (phase 2, status: completed)
Conditions: iron deficiency, iron deficiency anemia
ICD codes: E61.1, D50.8, D50.9, D50.0, D50.9, D50.0, D50.8
Drugs: ferric citrate, placebo
SMILES: [Fe+3], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Stage III to V Chronic Kidney Disease

          -  Serum Phosphorus 4.0-6.0 mg/dL prior to Randomization

          -  Ferritin 300 ng/mL or less

          -  Transferrin Saturation (TSAT) 30% or less

          -  Hemoglobin >9.0 and <12.0 g/dL

          -  Must consume a minimum of 2 meals per day

        Exclusion Criteria:

          -  Parathyroidectomy within 24 weeks of study

          -  gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study

          -  Requirement for dialysis or kidney injury within 8 weeks of study

          -  Absolute requirement for oral iron, intravenous iron, Erythropoiesis-Stimulating
             Agent, blood transfusions, and Sensipar during the study

          -  Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals

          -  Absolute requirement for vitamin C, niacin, or nicotinamide outside of multivitamins

          -  History of hemochromatosis

          -  Allergy to iron products

          -  History of malignancy in last 5 years
Clinical trial NCT00441883 (phase 2, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension, pigmentary glaucoma, pseudoexfoliative glaucoma
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: pf-03187207 and latanoprost vehicle, latanoprost 0.005% and pf-03187207 vehicle
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        -Diagnosis of primary open angle glaucoma (including pigmentary or pseudoexfoliative) or
        ocular hypertension in one or both eyes

        Exclusion Criteria:

        -Closed or barely open anterior chamber angle or a history of acute angle closure in either
        eye
Clinical trial NCT00104793 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, irinotecan hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed small cell lung cancer

               -  Extensive stage disease

          -  Newly diagnosed, treatment-naive disease

          -  At least 1 unidimensionally measurable lesion

          -  No massive pleural or pericardial effusion by chest CT scan

               -  Manageable effusions allowed

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Absolute granulocyte count ≥ 1,500/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

        Hepatic

          -  ALT or AST ≤ 2 times upper limit of normal

          -  Bilirubin ≤ 1.5 mg/dL

        Renal

          -  Creatinine normal

        Cardiovascular

          -  No myocardial infarction within the past year

          -  No uncontrolled hypertension

          -  No unstable angina

          -  No congestive heart failure

          -  No ventricular arrhythmia requiring medical intervention

          -  No other serious cardiovascular disease

        Pulmonary

          -  Arterial oxygen pressure (Pa O_2) ≥ 70 mm Hg

          -  No interstitial pneumonitis or pulmonary fibrosis by chest x-ray

        Other

          -  Not pregnant or nursing

          -  No uncontrolled diabetes

          -  No severe infection

          -  No paralytic or obstructive ileus

          -  No serious diarrhea

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix that is in complete
             remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy to the chest

               -  Other prior radiotherapy allowed

        Surgery

          -  At least 2 weeks since prior surgery and recovered
Clinical trial NCT00621855 (phase 2, status: completed)
Conditions: coronary disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: placebo, dabigatran etexilate, dabigatran etexilate, dabigatran etexilate, dabigatran etexilate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Eligibility criteria:

        Inclusion criteria Patients with acute coronary syndromes with at least one additional risk
        factor for cardiovascular complications.

        Exclusion criteria

          1. Long term treatment with any other oral anticoagulant

          2. Severe/disabling stroke within last 6 months

          3. Conditions associated with increased bleeding risk

          4. Anaemia or thrombocytopenia

          5. Severe renal impairment

          6. Liver disease

          7. Positive pregnancy test